ArticleClinical rheumatology2025
Clinical value of biomarkers in relation to artery size in eosinophilic granulomatosis with polyangiitis: findings from an inception cohort at a Japanese City Hospital.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesEosinophilic granulomatosis with polyangiitis (EGPA) is a necrotizing vasculitis that frequently affects small arteries in the skin and the nerve but can also involve the medium-sized arteries, resembling polyarteritis nodosa (PAN). This study aimed to evaluate the clinical value of biomarkers in EGPA in relation to the size of the affected arteries.
methodIn an inception cohort of EGPA, we examined the relationships between eosinophil counts, myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) positivity, levels of rheumatoid factor (RF) and Immunoglobulin E (IgE) and pre-defined outcomes based on artery size. These outcomes included histologically confirmed cutaneous vasculitis, glomerulonephritis, PAN-like arteritis in the cranial and abdominal arteries, and cardiomyopathy.
resultsIgE levels were significantly elevated in patients with cutaneous vasculitis and cardiomyopathy compared to those without the respective conditions. The median IgE values (range) were 3620 IU/mL (1160-6520) vs. 1000 IU/mL (229-5490) for cutaneous vasculitis (p = 0.0077), and 4065 IU/mL (1320-6520) vs. 1205 IU/mL (229-4030) for cardiomyopathy (p = 0.032). A numerically higher frequency of MPO-ANCA was observed in cases with PAN-like arteritis compared to those without (4/5 vs 8/25), similar to the findings for MPO-ANCA in glomerulonephritis. The crude odds ratio of MPO-ANCA positivity for both glomerulonephritis and PAN-like arteritis was 8.50 (95% CI: 1.05-181.45). The optimal IgE thresholds for detecting cutaneous vasculitis and cardiomyopathy were 1860 IU/mL and 2465 IU/mL, respectively, with areas under the curve of 0.82 and 0.84, indicating favorable diagnostic performance.
conclusionsIgE levels were associated with cutaneous vasculitis and cardiomyopathy in an inception cohort of EGPA in Japan. Further studies with larger cohorts are needed to confirm these findings, as our results are based on a retrospective study with a small sample size. Key Points • IgE levels were associated with cutaneous vasculitis in EGPA. • IgE levels were associated with cardiomyopathy in EGPA. • PAN-like arteritis tended to be associated with MPO-ANCA positivity.
Indexed as
Identifiers
40824340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.